Nycomed and Merck & Co have entered into a commercialisation agreement for Daxas, an investigational once-daily tablet for patients with chronic obstructive pulmonary disease.

Under the agreement, Nycomed will receive an upfront fee from Merck and certain payments based on specific regulatory and commercialisation milestones for Daxas.

Upon obtaining regulatory approval, the partners will co-promote Daxas in Canada, France, Germany, Italy, Portugal and Spain leveraging off Merck’s established sales force.

Nycomed will produce and distribute the drug in all the countries covered under the co-promotion agreement while Merck will have exclusive commercialisation rights in the UK.

Nycomed filed marketing applications for Daxas with the European Medicines Agency in 2009 following which it received a positive opinion from the agency recommending the drug approval in the European Union.

Nycomed also submitted a New Drug Application to the US Food and Drug Administration in July last year.